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MCO formulary managers for a migraine treatment that
has a good chance of relieving pain within 15 minutes,
allowing quick return to normal activities. We also found
that patients and physicians are willing to pay much more
than MCO formulary managers for other quality-of-life
beneﬁts, including preferred dosage form, nausea relief
and avoiding drowsiness.
CONCLUSIONS: The results support our hypothesis that
physicians and patients value quality-of-life beneﬁts more
highly than MCO formulary managers. However, the
sample sizes involved are too small to permit strong 
inference.
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Despite insomnia induces a great number of medical and
psychiatric visits, the role of co-morbidity in the medical
and professional consequences of this sleep disorder is
poorly documented.
OBJECTIVES: Our study seeks to evaluate the impact of
insomnia on the health status and absenteeism; and 
to identify the part of co-morbidity in the severity of
insomnia.
METHODS: We used data from the Gazel cohort (a
cohort of employees of the French electrical and gas
company) providing medical, professional and demo-
graphic information; the Epworth sleepiness scale; the
Nottingham Health Proﬁle; the Basic Nordic Sleep Ques-
tionnaire and a 3-week sleep log. Firstly, we compared a
group of insomniacs (n = 986) with another one free of
sleep complaints (n = 584). Secondly, all subjects suffer-
ing from mood and organic sleep complaints (snoring and
nocturnal periodic leg movements) were excluded.
RESULTS: In the non-adjusted by mood and organic
sleep complaints comparison (n = 986) we found a higher
absenteeism than in insomniac group than in control (9.6
+/- 31 days versus 5.8 +/- 19 days, U Mann-Withney, 
p < 0.01). However, no differences (6.39 vs. 6.02 days, 
U Mann-Withney, p = NS) in absenteeism between the
control group and insomniacs free of depression or
organic sleep complaints were observed. Nevertheless,
insomniacs (complaining or not of mood or organic sleep
complaints) showed a poorer health status deﬁned by the
Nottingham Health Proﬁle than control subjects.
CONCLUSIONS: Insomniac complaints are strongly
associated with an alteration of quality of life. Absen-
teeism in insomniacs is related to associated mood 
disorders or organic sleep complaints.
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OBJECTIVE: A French national epidemiological study 
on migraine was presented 10 years ago at the Migraine
trust. It was the ﬁrst study to cover an entire country
(HENRY P. et al.: Migraine prevalence in France. In New
advances in headache research: 2. Ed. Clifford Rose 1991
Smith Gordon-pp.: 11–14). This study has provided also
data on the burden of migraine in terms of its economic
and social impact. We would like today to update the
data.
METHODS: 1486 persons, aged over 15 and suffering
from headaches were randomly selected from a large 
representative sample of the French population. They
were asked to complete a questionnaire, which allowed 
discriminating sufferers of migraine according to IHS 
criteria.
RESULTS: Among the 1486 headache sufferers, we ﬁnd
880 migrainous people (1-1, 1-2 and 1-7 IHS criteria),
454 without migrainous headache and 152 with chronic
daily headache. If we compare the results of the certain
migraine group (1-1 and 1-2 IHS) we ﬁnd that they are
identical (8.1% (1989) versus 8.2% (1999)). However, if
we include the migrainous disorder group fulﬁlling all 
criteria but one (1-7 IHS), the prevalence rate for
migraine headache in France between 1989 and 1999
seems to show a clear increase, rising from 12.1% to
17.3% because of less restrictive criteria than those
applied ten years ago. Regarding the prevalence in general
population for chronic daily headache the rate is around
3% with 1.8% for men and 3.9% for women in 1999.
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OBJECTIVES: To identify through retrospective analy-
sis the difference in Glatiramer Acetate (Copaxone®)
therapy compliance between participants associated with
